FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of genetic engineering, molecular biology and vaccinology. Claimed is polyepitopic anti-tuberculosis vaccine construction for formation of immune response, which provides induction of immune response of CD8+ T-lymphocytes, consisting of universal polyepitopic immunogen, containing CTL-epitopes, selected from immunodominant antigens of M. tuberculosis, fused from N-end with ubiquitin, and having amino acid sequence SEQ ID NO: 1.
EFFECT: vaccine construction provides achievement of effective therapeutic T-cell immune response not only due to antigenspecific cytotoxic CD8+ T-lymphocytes but also intensive response of CD4+ T-lymphocytes.
1 tbl, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| POLYEPITOPE ANTI-TUMOUR VACCINE STRUCTURE CONTAINING EPITOPES OF TUMOR-ASSOCIATED ANTIGENS, PHARMACEUTICAL COMPOSITION AND ITS APPLICATION FOR STIMULATING SPECIFIC ANTI-TUMOR IMMUNE RESPONSE | 2016 |
|
RU2684235C2 |
| POLYEPITOPE IMMUNOGENIC POLYPEPTIDES AND METHODS OF APPLICATION THEREOF | 2013 |
|
RU2598265C2 |
| METHOD FOR STIMULATING CYTOTOXIC IMMUNE RESPONSE TO TUMOUR CELLS OF MAMMARY ADENOCARCINOMA EXPRESSING SPECIFIC ANTIGENS, WITH USE OF DENDRITE CELLS TRANSFECTED BY POLYEPITOPE DNA CONSTRUCT | 2012 |
|
RU2520091C2 |
| METHOD OF PRODUCING ANTIGEN-SPECIFIC CYTOTOXIC CELLS HAVING ACTIVITY AGAINST BREAST CANCER CELLS | 2013 |
|
RU2596920C2 |
| ARTIFICIAL GENE MEL-TCI, CODING POLYEPITOPIC PROTEIN-IMMUNOGENE MEL-TCI, RECOMBINANT PLASMID DNA PMEL-TCI PROVIDING EXPRESSION OF ARTIFICIAL GENE MEL-TCI AND ARTIFICIAL PROTEIN-IMMUNOGENE MEL-TCI, CONTAINING CTL- AND Th-DETERMINANTS OF MELANOMA ANTIGENES RESTRUCTURED BY PLURAL ALLELS HLA OF I AND II CLASS | 2017 |
|
RU2650872C1 |
| MEL-TCI-A0201 ARTIFICIAL GENE CODING MEL-TCI-A0201 POLYEPITOPE IMMUNOGENIC PROTEIN, RECOMBINANT PLASMID DNA OF pMEL-TCI-A0201, PROVIDING EXPRESSION OF MEL-TCI-A0201 ARTIFICIAL GENE AND MEL-TCI-A0201 ARTIFICIAL IMMUNOGENIC PROTEIN CONTAINING MULTIPLE CTL- AND Th-EPITOPES OF MELANOMA ANTIGENS | 2012 |
|
RU2522830C2 |
| METHOD FOR PRODUCTION OF IN VITRO POPULATIONS OF ACTIVATED ANTIGENSPECIFIC ANTITUMOR-TUMOR CYTOTOXIC T-LYMPHOCYTES SPECIFIC TO TUMOR-ASSOCIATED ANTIGEN EPITOPES | 2016 |
|
RU2619186C1 |
| RECOMBINANT PLASMID DNA pCI-UB-POLYEPI CONTAINING EPITOPES OF TUMOUR-ASSOCIATED ANTIGENS FOR COLORECTAL CANCER AND METHOD OF ITS APPLICATION FOR STIMULATION OF SPECIFIC ANTITUMOUR IMMUNE RESPONSE AGAINST COLORECTAL CANCER CELLS | 2012 |
|
RU2507265C2 |
| ARTIFICIAL GENE ENCODING THE BSI-COV IMMUNOGEN PROTEIN, PBSI-COV RECOMBINANT PLASMID DNA PROVIDING EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL BSI-COV POLYEPITOPE IMMUNOGEN PROTEIN CONTAINING EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2- SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806556C1 |
| ARTIFICIAL GENE ENCODING THE BSI-COV-UB IMMUNOGEN PROTEIN, RECOMBINANT PLASMID DNA PBSI-COV-UB, WHICH ENSURES THE EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL POLYEPITOPE BSI-COV-UB IMMUNOGEN PROTEIN CONTAINING UBIQUITIN AND EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2-SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806590C1 |
